STEM CELLS Translational Medicine Release: Stem Cell Treatment Speeds Up Recovery After Spinal Cord Injury In Monkeys
DURHAM, N.C., May. 27, 2015 /PRNewswire-iReach/ -- A new study appearing today in STEM CELLS Translational Medicine, designed to test how stem cell injections affect primates with spinal cord injury (SCI), showed the treatments significantly improved the animals' motor function recovery and promoted faster healing, too. The researchers call their findings a step forward toward the goal of improving outcomes for humans with chronic SCI.
Photo - http://photos.prnewswire.com/prnh/20150526/218475LOGO
Previous research conducted by various groups had indicated stem cell treatments helped rats with SCI. "But because there are distinct differences in the nervous system and immunological responses between rodents and primates, it is critical to determine how effective and safe the injections might be in a non-human primate SCI model as part of the translational research required for clinical trials," explained Hideyuki Okano, M.D., Ph.D., of Keio University School of Medicine's physiology department and a co-author of the new study.
In this study, the researchers grafted neural stem/progenitor cells (NS/PCs) derived from marmoset (a type of monkey) embryonic stem cells into adult marmosets suffering from a moderately bruised spinal cord. "The advantage of using common marmosets is the similarity between their nervous system and immunological responses and those of humans," Dr. Okano said.
The injections were given 14 days after the SCI occurred, which research shows is an optimal time window for SCI therapy as inflammation has generally subsided by then and scar tissue has not yet had time to form. (Doctors believe that an incomplete spinal cord injury, such as those of the study animals, offers better chance for recovery than a complete SCI injury.) The results were promising.
"Eventually, motor function recovery significantly improved in the transplantation group compared to a control group that did not receive stem cells," reported co-author Masaya Nakamura, M.D., Ph.D., of Keio's Department of Orthopedic Surgery. "An animal in the control group, for example, could not raise her hands up to head height at 12 weeks after injury when motor function almost plateaus. On the other hand, at the same point in time a transplanted animal was able to jump successfully and run so fast it was difficult for us to catch her. She could also grip a pen at 3 cm. above head-height."
In addition, he added, there were no signs of immune rejection or tumors, which have been a side effect of some stem cell therapies.
The researchers say this study is a step forward in their goal is to improve patients with complete SCI at the chronic phase. "But we believe it will require a combination of stem cell transplantation, rehabilitation and pharmacological therapy, with the stem cells a key part of the treatment," Dr. Okano added.
"This translational research using a nonhuman primate model is a critical step in eventually applying these cells to injured spinal cord in human patients," said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine.
The full article, "Allogeneic neural stem/progenitor cells derived from embryonic stem cells promote functional recovery after transplantation into injured spinal cord of non-human primates," can be accessed at http://www.stemcellstm.com.
About STEM CELLS Translational Medicine: STEM CELLS Translational Medicine (SCTM), published by AlphaMed Press, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.
About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS® (www.StemCells.com), celebrating its 33th year, is the world's first journal devoted to this fast paced field of research. The Oncologist® (www.TheOncologist.com), also a monthly peer-reviewed publication, entering its 20th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.
Media Contact:Nick Lively, AlphaMed Press, 9196800011, nick.lively@alphamedpress.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE STEM CELLS Translational Medicine
Help employers find you! Check out all the jobs and post your resume.